Italy · Delayed Price · Currency is EUR Pharmanutra Statistics
Total Valuation
Pharmanutra has a market cap or net worth of EUR 485.92 million. The enterprise value is 484.94 million.
| Market Cap | 485.92M |
| Enterprise Value | 484.94M |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | May 5, 2025 |
Share Statistics
Pharmanutra has 9.60 million shares outstanding. The number of shares has decreased by -0.58% in one year.
| Current Share Class | 9.60M |
| Shares Outstanding | 9.60M |
| Shares Change (YoY) | -0.58% |
| Shares Change (QoQ) | +2.76% |
| Owned by Insiders (%) | 10.77% |
| Owned by Institutions (%) | 12.75% |
| Float | 4.25M |
Valuation Ratios
The trailing PE ratio is 27.83 and the forward PE ratio is 22.90.
| PE Ratio | 27.83 |
| Forward PE | 22.90 |
| PS Ratio | 3.82 |
| PB Ratio | 7.36 |
| P/TBV Ratio | 11.66 |
| P/FCF Ratio | 47.62 |
| P/OCF Ratio | 33.63 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.50, with an EV/FCF ratio of 47.52.
| EV / Earnings | 27.79 |
| EV / Sales | 3.81 |
| EV / EBITDA | 15.50 |
| EV / EBIT | 17.12 |
| EV / FCF | 47.52 |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.19 |
| Quick Ratio | 1.86 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 0.67 |
| Debt / FCF | 2.06 |
| Interest Coverage | 35.71 |
Financial Efficiency
Return on equity (ROE) is 27.73% and return on invested capital (ROIC) is 20.77%.
| Return on Equity (ROE) | 27.73% |
| Return on Assets (ROA) | 15.04% |
| Return on Invested Capital (ROIC) | 20.77% |
| Return on Capital Employed (ROCE) | 31.94% |
| Revenue Per Employee | 1.08M |
| Profits Per Employee | 147,864 |
| Employee Count | 118 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 6.54 |
Taxes
In the past 12 months, Pharmanutra has paid 11.07 million in taxes.
| Income Tax | 11.07M |
| Effective Tax Rate | 38.98% |
Stock Price Statistics
The stock price has decreased by -9.55% in the last 52 weeks. The beta is 0.35, so Pharmanutra's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -9.55% |
| 50-Day Moving Average | 45.91 |
| 200-Day Moving Average | 48.76 |
| Relative Strength Index (RSI) | 58.27 |
| Average Volume (20 Days) | 30,005 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmanutra had revenue of EUR 127.33 million and earned 17.45 million in profits. Earnings per share was 1.82.
| Revenue | 127.33M |
| Gross Profit | 67.82M |
| Operating Income | 28.32M |
| Pretax Income | 28.39M |
| Net Income | 17.45M |
| EBITDA | 30.84M |
| EBIT | 28.32M |
| Earnings Per Share (EPS) | 1.82 |
Balance Sheet
The company has 21.97 million in cash and 20.98 million in debt, giving a net cash position of 981,000 or 0.10 per share.
| Cash & Cash Equivalents | 21.97M |
| Total Debt | 20.98M |
| Net Cash | 981,000 |
| Net Cash Per Share | 0.10 |
| Equity (Book Value) | 66.07M |
| Book Value Per Share | 6.85 |
| Working Capital | 36.99M |
Cash Flow
In the last 12 months, operating cash flow was 14.45 million and capital expenditures -4.24 million, giving a free cash flow of 10.21 million.
| Operating Cash Flow | 14.45M |
| Capital Expenditures | -4.24M |
| Free Cash Flow | 10.21M |
| FCF Per Share | 1.06 |
Margins
Gross margin is 53.26%, with operating and profit margins of 22.24% and 13.70%.
| Gross Margin | 53.26% |
| Operating Margin | 22.24% |
| Pretax Margin | 22.29% |
| Profit Margin | 13.70% |
| EBITDA Margin | 24.22% |
| EBIT Margin | 22.24% |
| FCF Margin | 8.01% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 1.98%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 1.98% |
| Dividend Growth (YoY) | 17.65% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 54.97% |
| Buyback Yield | 0.58% |
| Shareholder Yield | 2.50% |
| Earnings Yield | 3.59% |
| FCF Yield | 2.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |